ArticleHemaSphere2024

Disease-burden-adapted immunotherapy protocol for primary refractory or high-risk relapsed pediatric acute lymphoblastic leukemia.

Sanaa Khan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.